Treatment with EPs® 7630 reduces illness absence from childcare due to acute bronchitis

2024-02-13

Recently, a meta-analysis was published which considered and analyzed the available randomized, placebo-controlled clinical trials with EPs® 7630 in children and adolescents. The research question was to what extent treatment with EPs® 7630 for acute bronchitis reduces the average time of illness absence from kindergarten, school, or training in this patient group.

The results of the meta-analysis show that treatment with EPs® 7630 for 7 days significantly reduced the average time of illness absence from kindergarten, school, or training due to acute bronchitis by about 1,5 days. Moreover, the proportion of patients able to return to normal activities within 1 week was significantly increased in children and adolescents treated with EPs® 7630 compared to those treated with placebo.

A reduction in illness absence from kindergarten, school, or training not only means a shorter miss of learning for the patients, but also a shorter period of time, during which parents of younger children need a parental plan B for childcare.
 

The original publication Zwiauer K, Funk P, Zimmermann A, Lehmacher W, Kamin W. Effects of EPs 7630 on the duration of inability to work in acute bronchitis – a meta-analysis. J Pediatr Infect Dis 2024; Issue EFirst. DOI: 10.1055/s-0043-1777092. is available for free on the homepage of the journal
www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0043-1777092#info.
 

Meta-analyses are considered in science as the highest evidence of efficacy.